| Market Cap | 11.80M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -5.26M | Forward P/E | -3.14 | EPS next Y | - | 50D Avg Chg | -15.00% |
| Sales | 19.97M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -33.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -63.00% |
| Recommedations | 2.00 | Quick Ratio | 0.10 | Shares Outstanding | 63.87M | 52W Low Chg | 210.00% |
| Insider Own | 43.62% | ROA | -1.28% | Shares Float | 35.99M | Beta | 1.55 |
| Inst Own | 0.07% | ROE | - | Shares Shorted/Prior | 41.22K/33.64K | Price | 0.22 |
| Gross Margin | 95.48% | Profit Margin | -26.32% | Avg. Volume | 6,920 | Target Price | - |
| Oper. Margin | 10.82% | Earnings Date | Nov 12 | Volume | 50 | Change | 0.00% |
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Its pipeline products include ELS001/ELS007, a pharmaceutical grade L-glutamine, which has completed phase 3 clinical trial to treat sickle cell disease; ELS004, a pharmaceutical grade L-glutamine which has completed phase 1 clinical study to treat diverticulosis; ELS005 in preclinical study for the use and combination of KM10544 to treat blood cancers; ELS003, a lab device/research tool in preclinical study to measure transmittance of cell sheet; and ELS002, a chondrocyte cell sheet technology to replace knee cartilage replacement or to treat osteoarthritis is in preclinical study. It has a license agreement with Kainos Medicine, Inc., which includes the patent rights of IRAK4 inhibitor (KM10544) for the treatment of cancers. The company was founded in 2000 and is headquartered in Torrance, California.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Lim Seah H. | Director Director | Dec 20 | Sell | 0.05 | 32,500 | 1,625 | 4,586,626 | 12/21/23 |
| Lim Seah H. | Director Director | Oct 09 | Sell | 0.11 | 6,000 | 660 | 171,700 | 12/19/23 |
| Lim Seah H. | Director Director | Oct 09 | Buy | 0.17 | 139,200 | 23,664 | 177,700 | 12/19/23 |
| LEE WILLIS C | COO COO | Aug 25 | Buy | 0.14 | 15,609 | 2,185 | 395,124 | 12/04/23 |
| Niihara Yutaka | Chairman and CEO Chairman and CEO | Nov 03 | Buy | 0.41 | 52,600 | 21,566 | 12,040,857 | 12/01/22 |
| Niihara Yutaka | Chairman and CEO Chairman and CEO | Oct 24 | Buy | 0.29 | 69,400 | 20,126 | 11,960,757 | 10/31/22 |
| Niihara Yutaka | Chairman and CEO Chairman and CEO | Oct 19 | Buy | 0.18 | 65,000 | 11,700 | 11,891,357 | 10/24/22 |
| Niihara Yutaka | Chairman and CEO Chairman and CEO | Oct 17 | Buy | 0.2 | 45,000 | 9,000 | 11,826,357 | 10/19/22 |
| Niihara Yutaka | Chairman and CEO Chairman and CEO | Oct 13 | Buy | 0.18 | 97,500 | 17,550 | 11,781,357 | 10/17/22 |
| LEE WILLIS C | COO COO | Jul 19 | Buy | 0.39 | 3,200 | 1,248 | 286,974 | 07/25/22 |
| LEE WILLIS C | Director & COO Director & COO | May 27 | Buy | 0.39 | 5,000 | 1,950 | 283,774 | 06/03/22 |
| Niihara Yutaka | Chairman and CEO Chairman and CEO | May 20 | Buy | 0.5 | 7,000 | 3,500 | 11,333,857 | 06/02/22 |
| LEE WILLIS C | Director & COO Director & COO | Apr 04 | Buy | 0.89 | 15,100 | 13,439 | 278,774 | 04/12/22 |
| Niihara Yutaka | Chairman and CEO Chairman and CEO | Feb 28 | Buy | 1.49 | 53,800 | 80,162 | 11,303,506 | 03/02/22 |
| LEE WILLIS C | Vice Chairman & COO Vice Chairman & COO | Feb 22 | Buy | 1.5 | 21,100 | 31,650 | 1,900 | 02/28/22 |
| Niihara Yutaka | Chairman and CEO Chairman and CEO | Feb 18 | Buy | 1.44 | 19,300 | 27,792 | 11,233,206 | 02/23/22 |
| Niihara Yutaka | Chairman and CEO Chairman and CEO | Feb 16 | Buy | 1.45 | 7,500 | 10,875 | 11,213,906 | 02/18/22 |
| Niihara Yutaka | Chairman and CEO Chairman and CEO | Feb 14 | Buy | 1.45 | 12,000 | 17,400 | 11,206,406 | 02/16/22 |
| Niihara Yutaka | Chairman and CEO Chairman and CEO | Feb 09 | Buy | 1.46 | 30,500 | 44,530 | 11,194,406 | 02/11/22 |
| Niihara Yutaka | Chairman and CEO Chairman and CEO | Feb 07 | Buy | 1.48 | 8,500 | 12,580 | 11,163,906 | 02/09/22 |
| Niihara Yutaka | Chairman and CEO Chairman and CEO | Feb 03 | Buy | 1.42 | 13,250 | 18,815 | 11,155,406 | 02/07/22 |
| LEE WILLIS C | Vice Chairman & COO Vice Chairman & COO | Nov 26 | Buy | 1.47 | 55,533 | 81,634 | 228,394 | 11/30/21 |